關鍵數據
71.500今開
71.570最高
560.43K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
1.36%換手率
71.140昨收
67.160最低
27.13M成交額
虧損本益比靜
1.13市淨率
0.00%股息率 TTM
-13.99%ROA
118.84052週最高
0.98量比
-2.03B淨利潤
41.13M總股本
-10.3076每股盈餘TTM
--Beta
-16.09%ROE
29.95052週最低
6.20%振幅
-35.08%毛利率
2.94B總市值
0.68回報/風險
4.69%風險率
操作建議
Grail Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名62/385位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為68.39。中期看,股價處於上升通道。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Grail Inc新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
Ionis Pharmaceuticals Inc
IONS
26
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Grail Inc簡介
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代碼GRAL
公司Grail Inc
CEORagusa (Robert)
網址https://grail.com/
公司股東
常見問題
Grail Inc(GRAL)的當前股價是多少?
Grail Inc(GRAL)的當前股價是 68.56。
Grail Inc股票的52週最高點是118.84。
Grail Inc股票的52週最低點是29.95。
現在Grail Inc(GRAL)的股票是買入、持有還是賣出?
根據分析師評級,Grail Inc(GRAL)的總體評級為買入,目標價格為68.39。
Grail Inc(GRAL)股票的每股收益(EPS TTM)是多少
Grail Inc(GRAL)股票的每股收益(EPS TTM)是-11.11。